Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PDGF R alpha

PDGF R alpha

Brief Information

Name:Platelet-derived growth factor receptor alpha
Target Synonym:RHEPDGFRA,Platelet-derived growth factor alpha receptor,PDGFRA,Alpha-type platelet-derived growth factor receptor,PDGFR-alpha,CD140a antigen,CD140a,Platelet Derived Growth Factor Receptor Alpha,Platelet-Derived Growth Factor Receptor, Alpha Polypeptide,Platelet-Derived Growth Factor Receptor 2,CD140 Antigen-Like Family Member A,PDGF-R-Alpha,PDGFR-2,PDGFR2,Platelet-Derived Growth Factor Receptor Alpha,Alpha Platelet-Derived Growth Factor Receptor,Receptor, Platelet-Derived Growth Factor alpha,GAS
Number of Launched Drugs:8
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
PDA-H52H7 Human Human PDGF R alpha / PDGFRA Protein, His Tag
PDA-H52H7-structure
PDA-H52H7-sds

Synonym Name

PDGFRA,CD140A,PDGFR2,RHEPDGFRA,MGC74795

Background

PDGFRA(platelet-derived growth factor receptor A), also termed PDGFR?(platelet-derived growth factor receptor ?), is a receptor located on the surface of a wide range of cell types. This receptor binds to certain isoforms of platelet-derived growth factors (PDGFs) and thereby becomes active in stimulating cell signaling pathways that elicit responses such as cellular growth and differentiation. The receptor is critical for the development of certain tissues and organs during embryogenesis and for the maintenance of these tissues and organs, particularly hematologic tissues, throughout life. Mutations in the gene which codes for PDGFRA, are associated with an array of clinically significant neoplasms.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Avapritinib BLU-285; CS-3007 Approved Blueprint Medicines Corp Ayvakit, Ayvakyt, 泰吉华 Hong Kong Gastrointestinal Stromal Tumors Cstone Pharmaceuticals 2020-01-09 Solid tumours; Hematologic Neoplasms; Mastocytosis, Systemic; Leukemia, Mast-Cell; Central Nervous System Neoplasms; Gastrointestinal Stromal Tumors Details
Pazopanib Hydrochloride GW-786034; SB-786034; GSK-786034; GW-786034B Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Patorma, Votrient Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Osteosarcoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Sarcoma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hemangiosarcoma; Carcinoma, Renal Cell; Solid tumours; Chondrosarcoma; Telangiectasia, Hereditary Hemorrhagic Details
Ripretinib DCC-2618 Approved Deciphera Qinlock, 擎乐 United Kingdom Gastrointestinal Stromal Tumors Deciphera Pharmaceuticals Llc 2020-05-15 Mastocytosis, Systemic; Gastrointestinal Stromal Tumors Details
Regorafenib DAST; BAY-73-4506 Approved Bayer Ag Resihance, Stivarga Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Olaratumab IMC-3G3; LY-3012207 Approved Eli Lilly And Company Lartruvo United States Sarcoma Eli Lilly And Company 2016-10-19 Solid tumours; Sarcoma; Prostatic Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Endometrial Neoplasms Eisai Co Ltd 2015-02-13 Liver Diseases; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD Approved Pfizer Pharmaceuticals Ltd (China) Sutent, 索坦 Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Breast Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Diabetic macular oedema; Prostatic Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Stomach Neoplasms; Carcinoma, Islet Cell; Carcinoma, Renal Cell; Liver Neoplasms; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CMV monoclonal antibody (Humabs BioMed/Institute for Research in Biomedicine) Phase 2 Clinical Humabs Biomed, Institute For Research In Biomedicine Cytomegalovirus Infections Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Crenolanib Besylate ARO-002; CP-868596; ARO-002-26; IND-112201; CP-868596-26 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Non-Small-Cell Lung Details
Chiauranib CS-2164 Phase 3 Clinical Shenzhen Chipscreen Biosciences Co Ltd Solid tumours; Ovarian Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message